BioAsia 2015 hosts thoughtful sessions on day 2

Telangana State Industrial Infrastructure Corporation (TSIIC) also signed a Memorandum of Understanding with China Medical City. The MoU was signed by Jayesh Ranjan, Vice Chairman and Managing Director, TSIIC and Liu Lu, Deputy Director, China Medical City in the presence of Jupally Krishna Rao.

Speaking on this occasion Shakthi Nagappan, CEO, BioAsia said, “We are overwhelmed with the sessions, panel discussions and response as we have 750 registered participants on Day 2. We are sure that the delegates are getting an opportunity to explore new opportunities and upcoming trends from the eminent speakers. The participation of key industry leaders and signing of MoU between Telangana state and China Medical City today is a testimony to the role that BioAsia has played in bringing together all stakeholders for an inclusive growth and knowledge sharing.”

The Drug Discovery Conference at BioAsia 2015 focused on showcasing India’s innovation pipeline. The session topics included ‘Doing more with less – Accelerating India’s Biopharmaceutical Discovery’, ‘Collaborating to bring effective treatment to market’,



‘Investing in the NEW’ and ‘Funding drug discovery’.

The Rapid Diagnostics conference featured experts from diverse domains and topics ranging from the analysis of existing knowledge and the future of rapid diagnostic and POC Tests, not only in health care but across all allied fields of life sciences were covered. The conference examined how rapid diagnostics are being used in clinics, in pharmacies, and by the consumers. The focus of the conference was to identify potential gaps in the market for new technologies and learn how to successfully implement these in a highly competitive market place on a need base.

The ‘Supply Chain and Logistics ‘conference was focused to enable companies to identify new emerging market trends for a cost effective pharma supply chain management. As Indian companies look to penetrating the market locally and supply to global markets, an agile, customized and cost-efficient supply chain is of paramount importance. Companies in many industries have pruned their supply chain costs to support profitable growth. Until recently, pharmaceutical companies did not embrace this trend. The pharmaceutical supply chain is facing many challenges and will need a radical overhaul.

BioAsia 2015 is organised by the Federation of Asian Biotech Association [FABA], Government of Telangana and the Pharmaceutical Export Promotion Council (Pharmexcil) with the support of Government of India. Public Health Foundation of India (PHFI), PricewaterhouseCoopers (PwC), Biotech Industry Research Assistance Council (BIRAC)-GoI, TiE-Hyderabad, Organization of Pharmaceutical Producers of India (OPPI), Nizams Institute of Medical Sciences (NIMS), Indian Medical Association (IMA), FICCI – Food 360, Association of Contract Research Organizaions (ACRO), Aurigene Discovert, Invest India and India Brand Equity Foundation among other organizations.